

DMD # 83444

TITLE: Oral co-administration of fluconazole with tramadol markedly increases plasma and urine concentrations of tramadol and the *O*-desmethyltramadol metabolite (M1) in healthy dogs

Tania E. Perez Jimenez, Butch Kukanich, Hyun Joo, Katrina L. Mealey, Tamara L. Grubb, Stephen A. Greene, and Michael H. Court

Program in Individualized Medicine (PrIME), Pharmacogenomics Laboratory, Department of Veterinary Clinical Sciences, Washington State University College of Veterinary Medicine. (T.E.P.J., K.L.M., T.L.G., S.A.G., M.H.C.)

Department of Anatomy and Physiology, Institute of Computational Comparative Medicine, Kansas State University College of Veterinary Medicine. (B.K., H.J.)

DMD # 83444

Running title. Fluconazole increases tramadol and M1 in dog plasma and urine

Corresponding author: Tania E Perez DVM, MS, PhD, Program in Individualized Medicine (PrIME), Pharmacogenomics Laboratory, Department of Veterinary Clinical Sciences, Washington State University College of Veterinary Medicine, 100 Grimes Way, Pullman, WA 99164, USA. Telephone: 509-335-0705; Fax: 509-335-0880; Email: teperezjimenez@wsu.edu.

Counts:

Text pages: 20

Tables: 6

Figures: 5

References: 33

Abstract words: 250

Introduction words: 584

Discussion words: 1519

Nonstandard abbreviations: M1 – *O*-desmethyltramadol; M2 – *N*-desmethyltramadol; M5 – *N,O*-didesmethyltramadol; DLMS – dog liver microsomes; HPLC – high performance liquid chromatography; MS – mass spectrometry; GMR – geometric mean ratio

DMD # 83444

ABSTRACT

Tramadol is used frequently in the management of mild to moderate pain conditions in dogs. This use is controversial because multiple reports in treated dogs demonstrate very low plasma concentrations of O-desmethyltramadol (M1), the active metabolite. The objective of this study was to identify a drug that could be co-administered with tramadol to increase plasma M1 concentrations thereby enhancing analgesic efficacy. In vitro studies were initially conducted to identify a compound that inhibited tramadol metabolism to N-desmethyltramadol (M2) and M1 metabolism to N,O didesmethyltramadol (M5) without reducing tramadol metabolism to M1. A randomized crossover drug-drug interaction study was then conducted by administering this inhibitor or placebo with tramadol to 12 dogs. Blood and urine samples were collected to measure tramadol, tramadol metabolites, and inhibitor concentrations. After screening 86 compounds, fluconazole was the only drug found to inhibit M2 and M5 formation potently without reducing M1 formation. Four hours after tramadol administration to fluconazole-treated dogs, there were marked statistically significant ($P < 0.001$; Wilcoxon signed-rank test) increases in plasma tramadol (31-fold higher) and M1 (39-fold higher) concentrations when compared to placebo-treated dogs. Conversely, plasma M2 and M5 concentrations were significantly lower (11-fold and 3-fold, respectively; $P < 0.01$) in fluconazole-treated dogs. Metabolite concentrations in urine followed a similar pattern. This is the first study to demonstrate a potentially beneficial drug-drug interaction in dogs through enhancing plasma tramadol and M1 concentrations. Future studies are needed to determine whether adding fluconazole can enhance the analgesic efficacy of tramadol in healthy dogs and in clinical patients experiencing pain.

DMD # 83444

INTRODUCTION

Tramadol is frequently used in the management of mild to moderately painful conditions in dogs (Gaynor, 2008; Lamont, 2008). The acute analgesic properties of tramadol are thought to derive largely from effects on μ -opioid receptors in the central nervous system (Raffa et al., 1992). Tramadol itself shows relatively weak affinity for opioid receptors in cell based and animal studies. However, after administration, tramadol is metabolized by cytochrome P450 (CYP) enzymes to *O*-desmethyltramadol (M1) that has about 200-times higher affinity for the μ -opioid receptor than the parent compound (Raffa et al., 1992). Opioid receptor independent effects of tramadol have also been identified, including inhibition of norepinephrine and serotonin reuptake transporters, which may contribute to analgesic effects, especially with chronic tramadol dosing (Raffa et al., 1992; Aronson, 1997).

Tramadol metabolism has been investigated extensively in humans, but only recently has it been studied in detail in veterinary medicine, particularly in dogs (Giorgi et al., 2009; Kukanich and Papich, 2011; Perez Jimenez et al., 2016). In addition to metabolism to (M1), tramadol is metabolized extensively to *N*-desmethyltramadol (M2). Both M1 and M2 are also further metabolized to *N,O*-didesmethyltramadol (M5), which is the major metabolite found in the plasma and urine of dogs given tramadol (Kukanich and Papich, 2011). Tramadol, M1, M2, and M5 can also be further metabolized by conjugation, including both glucuronidation and sulfation (Grond et al., 1999).

One consistent finding of these pharmacokinetic studies is the relatively low circulating concentrations of M1 in dogs when compared to other species, including humans (Scott and Perry, 2000) and cats (Pypendop et al., 2009) even when adjusted for differences in tramadol dose. Such low concentrations of M1 in dogs may have clinical consequences in that multiple studies have

DMD # 83444

failed to demonstrate significant analgesic effects, at least when compared to other commonly used analgesic drugs (Davila et al., 2013; Delgado et al., 2014; Kogel et al., 2014). In contrast, studies of tramadol in cats have consistently demonstrated analgesic efficacy (Pypendop et al., 2009; Evangelista et al., 2014), which is accompanied by much higher plasma M1 concentrations (Pypendop et al., 2009; Cagnardi et al., 2011). Consequently, increasing plasma M1 concentrations such as through selective inhibition of tramadol and M1 metabolic pathways is a plausible strategy that could lead to enhanced analgesic effects of tramadol in dogs.

In previous studies, we demonstrated that tramadol is metabolized by dog liver microsomes (DLMs) to M1 mainly by CYP2D15 and to M2 by CYP2B11 and CYP3A12, which are species orthologs of CYP2D6, CYP2B6 and CYP3A4 (respectively) that perform the same function in humans (Subrahmanyam et al., 2001; Perez Jimenez et al., 2016). We also went on to show that CYP2C21 is mainly responsible for the formation of M5 from M1 and that CYP2D15 is exclusively responsible for formation of M5 from M2 (Perez Jimenez et al., 2018). CYP phenotyping of these secondary pathways have not yet been reported for human enzymes, as far as we are aware.

The purpose of this study was to identify a drug that could be co-administered with tramadol to increase plasma M1 concentrations, thereby enhancing analgesic effectiveness. We used a two-step approach. Firstly, we conducted an *in vitro* screen using DLMs to identify a drug that selectively inhibits M2 formation from tramadol and M5 formation from M1, without inhibiting M1 formation from tramadol. We then conducted a proof-of-principle drug-drug interaction study in healthy dogs to test the hypothesis that the identified drug would increase plasma and urine concentrations of tramadol and M1, while decreasing concentrations of M2 and M5.

DMD # 83444

MATERIALS AND METHODS

Reagents

NADP⁺, isocitrate dehydrogenase, DL-isocitrate and fluconazole were obtained from Sigma-Aldrich (St. Louis, MO). (+)-tramadol hydrochloride (#T712515), (-)-tramadol (#T712520), *O*-desmethyltramadol hydrochloride (#D294740), *O*-desmethyltramadol-D₆ (#D294742), *N*-desmethyltramadol (#D294700), *N*-desmethyltramadol-D₃ hydrochloride (#D294702) and *N,O*-didesmethyl tramadol-d₃ hydrochloride (#D441217) were purchased from Toronto Research Chemicals Inc. (Toronto, Ontario, Canada). Tramadol-¹³C, D₃ HCl (T-029) was from Cerilliant (Round Rock, TX). Racemic (±)-tramadol was made by combining equal amounts of (+)-tramadol and (-)-tramadol.

Liver microsomes were prepared as previously described (Court et al., 1997) from a bank of frozen dog livers maintained at Washington State University. Livers were from 59 untreated adult dogs including 25 beagles (6 females, 19 males), 5 greyhounds (all males), 12 mixed breed dogs (6 females and 6 males), 4 Chihuahuas (3 males and 1 female), 12 hounds (all females) and one Labrador retriever (male). All dogs were healthy and were euthanized for reasons unrelated to this study. The collection of the dog livers was approved by the Institutional Animal Care and Use Committee Washington State University (IACUC #04412). The microsomal protein content of the DLMs used in this study were measured using the bicinchoninic acid assay (Thermo Scientific Pierce, Rockford, Illinois).

Assay to screen for inhibitors of M1 and/or M2 formation from tramadol

Eighty-five compounds (listed in Table 1) were screened as potential inhibitors of M1 and M2 formation from tramadol in pooled DLMs. These compounds were obtained as pure chemicals

DMD # 83444

from Sigma-Aldrich (St Louis, MO), or from the following sources. Acepromazine maleate (PromAce) and meloxicam (Metacam) were from Boehringer Ingelheim Vetmedica Inc. (St Joseph, MO). Atipamezole (antisedan), and dexmedetomidine HCl (Dexdomitor) were from Orion Pharma (Espoo, Finland). Bupivacaine HCL (Sensorcaine) was from APP Pharmaceuticals LLC (Lake Zurich, IL). Propofol (Propoflo28) was from Abbott Laboratories (North Chicago, IL). Lidocaine HCl and fentanyl citrate were from Hospira, Inc (Lake Forest, IL). Carprofen (Rimadyl), maropitant citrate (Cerenia) and ketamine HCl (Ketaset) were from Zoetis Inc (Kalamazoo, MI). Hydromorphone HCl was from West-Ward (Eatontown, NJ). Midazolam was from Akorn Inc (Lake Forest, IL). Alfaxalone (Alfaxan) was from Jurox Pty Limited (Rutherford, NSW, Australia). All compounds were dissolved in methanol at two concentrations (1 and 100 μM), added to 2 mL polypropylene Eppendorf incubation tubes, and dried down in a centrifugal vacuum. NADPH cofactor mix and 20 μg of DLMS were added to the tubes and pre-incubated at 37°C for 15 minutes. Tramadol (5 μM final concentration) was then added and incubated for further 10 minutes. The reaction was stopped by adding internal standard and the metabolites formed were measured by HPLC-MS as described previously (Perez Jimenez et al., 2016).

Determination of potency of inhibition by fluconazole

The potency (measured as half-maximal inhibitory concentration [IC_{50}] values) of fluconazole as an inhibitor of M1 and M2 formation from tramadol and M5 formation from M1 and M2 was determined at multiple concentrations in pooled DLMS. Fluconazole was dissolved in methanol at 0.001, 0.01, 0.1, 1, 10, 100, 1000 μM concentrations, added to incubation tubes, and dried in a centrifugal vacuum. NADPH cofactor mix and enzyme (20 μg of DLMS for tramadol metabolism to M1 and M2; 10 μg of DLMS for M1 metabolism to M5; and 5 μg of DLMS for M2 metabolism to M5 formation) were added to the tube and pre-incubated at 37°C for 15

DMD # 83444

minutes. Substrate including tramadol (5 μM), M1 (10 μM) or M2 (0.5 μM) were then added and incubated for a further 10 minutes, 20 minutes and 5 minutes respectively. The reaction was stopped by adding internal standard and the metabolites formed were measured by HPLC-MS as described in detail previously [(Perez Jimenez et al., 2016); (Perez Jimenez et al., 2018)]. Samples were prepared in triplicate. M1, M2 and M5 formation rates were averaged, and then expressed as a percentage of control incubations that lacked inhibitor. IC_{50} values were determined using nonlinear regression with a four-parameter logistic curve (Sigmaplot version 13 software, Systat, San Jose, CA).

An inhibition constant (K_i) was also determined for the inhibition of M2 formation from tramadol in DLMS by using varying tramadol concentrations of tramadol (0, 5, 10, 20, 50, 100, 200, 500 μM) and fluconazole concentrations (0, 0.1, 1, 10, 100 μM). Incubations and HPLC-MS analysis were performed as above. Nonlinear regression analysis (Sigmaplot version 13 software, Systat, San Jose, CA) was used to derive fitted parameter estimates including K_i , K_m , and V_{max} , using the competitive, noncompetitive, uncompetitive, and mixed competitive-noncompetitive enzyme inhibition models using the approach described previously (Venkatakrishnan et al., 2001).

In vivo drug-drug interaction study

We conducted a 2-way randomized crossover drug-drug interaction trial with a blinded observer. Based on published data (Kukanich and Papich, 2011) the mean and standard deviation of the plasma M1 concentrations were 6.3 and 2.9 ng / mL, respectively. We proposed to detect a minimum 50% change in M1 concentration, with a 0.85 power, at a P -value of less than 0.05 using a paired t-test. Although sample size analysis indicated that we would need to study at least 10 dogs, we elected to study 12 dogs to allow for up to two potential subject dropouts before the end of the study. This study was reviewed and approved by the Institutional Animal Care and Use

DMD # 83444

Committee at Washington State University (ASAF # 04729). All owners gave written informed consent for their dog to participate.

Study subjects

Twelve healthy owned dogs were recruited from among the staff, faculty and students at the College of Veterinary Medicine at Washington State University (Pullman, WA). Health was determined by physical examination, history, complete blood count, and serum biochemistry profile, performed at the Veterinary Teaching Hospital (VTH), Washington State University. Dogs were between 2.5 and 7 years old (average 4 years old), included 6 males and 6 females, weighed between 20 and 35 kg (average 26 kg), and had not been treated with any other medications within 2 weeks prior to or at the time of the study. Various dog breeds were represented, including Labrador retriever mix (3), German shepherd (1), flat-coated retriever (1), Australian shepherd mix (1), pit bull mix (1) Australian cattle dog/heeler mix (1), boxer mix (1), golden retriever mix (1), German shepherd mix (1) and a wire-haired pointing griffon (1). All dogs were fasted by the owners on the morning of the study and were housed in kennels in the Veterinary Teaching Hospital at Washington State University. Blood sampling was performed in a room designated for the study inside the hospital.

Study design

Pill pockets (Canine Greenies, The Nutro Company, Franklin, TN) were filled by the VTH pharmacist with either placebo (empty gelatin capsules) or fluconazole (4 mg/kg dose; WellSpring Pharmaceutical, Ontario, Canada). These were labelled as treatment A and treatment B (respectively) and this code was maintained by the pharmacist until the completion of the study. The filled pill pockets were given to the owners to be administered at approximately 24 hours (the

DMD # 83444

prior morning) and 12 hours (the prior night) before the day of the testing. Randomization of the initial treatment that each dog received was achieved by drawing from a bag a piece of paper labelled with the treatment identification (A: placebo; B: fluconazole). Six dogs received treatment A first, while 6 dogs received treatment B first. On the morning of the day of testing the dogs were given a third pill pocket containing the assigned treatment (A or B) and 30 minutes later another pill pocket containing tramadol (5 mg/kg dose; Amneal Pharmaceuticals, Hauppauge, NY) was administered. There was a minimum 2-week wash-out period between treatments to account for possible residual drug effect. The code identifying the treatments as either placebo or fluconazole was revealed by the pharmacist after completion of sample and data analysis.

Heparinized 5 mL blood samples were collected aseptically from a peripheral vein immediately before tramadol administration (time 0) and at 1 and 4 hours after tramadol administration. Urine samples were taken by free catch at 4 hours after tramadol administration. Blood plasma was separated shortly after collection, and stored with the urine samples at -80°C until assay for drug and metabolite concentrations by HPLC-MS.

Assays for drug and metabolite concentrations in plasma and urine samples

Plasma and urine samples were assayed for tramadol, M1, M2 and M5 concentrations with and without deconjugation. The deconjugation solution was sodium acetate buffer (200 mM, pH 5.0) that contained 1666 U/mL of β -glucuronidase (β -glucuronidase type L-II from limpets, G8132 Sigma Aldrich, St Louis, MO, USA). For each sample, 150 μ L of the deconjugation solution was added to 50 μ L of plasma or urine and incubated for 3 hours at 65 °C. Untreated plasma and urine samples were mixed with the same buffer without β -glucuronidase added, and incubated similarly. An aliquot (50 μ L) of the incubation sample was then added to 100 μ L of 0.1 % (v/v) formic acid in water containing the internal standards (at 200 ng/mL each). Internal standards were tramadol-

DMD # 83444

$^{13}\text{C}_3\text{D}_3$ (for tramadol), M1-D₆ (for M1 and M5), and M2-D₃ (for M2). Phosphoric acid (150 μL at 4% v/v in water) was then added and mixed. Elution plates (Oasis MCX 50 μm , Waters Corporation, Milford, MA, USA) were first conditioned with 150 μL of methanol, followed by 150 μL deionized water. The samples were passed through the plate and washed with 150 μL of 2% (v/v) formic acid in deionized water followed by 150 μL of methanol. The samples were then eluted with two consecutive 25 μL volumes of 5% (v/v) ammonium hydroxide in methanol. The eluate was diluted with 100 μL of deionized water prior to analysis by liquid chromatography-mass spectrometry.

Plasma sample preparation for measurement of fluconazole concentrations involved mixing 15 μL of sample with 35 μL untreated (blank) plasma and 100 μL of acetonitrile with 1% formic acid containing the internal standard voriconazole at 1 $\mu\text{g}/\text{mL}$. This was passed through a phospholipid removal plate (Ostro Pass-through Plates, Water Corporation, Milford, MA USA) and 2 μL of the eluate was injected into the liquid chromatography-mass spectrometry instrument.

Drug and metabolite concentrations were determined using a liquid chromatography instrument (Acquity UPLC H-Class UPLC, Waters Corporation, Milford, MA USA) with a triple quadrupole mass spectrometry detector (TQD, Waters Corporation, Milford, MA USA). The mobile phase included: A, 0.1% formic acid in deionized water, and B, acetonitrile at a flow rate of 0.6 mL/minute. A gradient was used that began with 85% A to 5% A at 0.8 minutes which was held until 1.3 minutes followed by a return to 85% A at 1.31 minutes with a total run time of 2.2 minutes. The column (Acquity UPLC HSS T3 1.8 μm , Waters Corporation, Milford, MA USA) was heated to 40 $^\circ\text{C}$. The mass to charge ratio (m/z) for the qualifying and quantifying positive ions (m/z qualifying ion \rightarrow quantifying ions) were: fluconazole = m/z 307.27 \rightarrow 169.06, 220.14; voriconazole = m/z 350.09 \rightarrow 126.97, 281.06; tramadol = m/z 264.20 \rightarrow 58.06; tramadol- $^{13}\text{C}_3\text{D}_3$ =

DMD # 83444

m/z 268.21 \rightarrow 58.05, 91.96; M1 = m/z 250.12 \rightarrow 57.99; M1-D₆ = m/z 256.18 \rightarrow 45.65, 63.98; M2 = m/z 250.12 \rightarrow 44.04; M2-D₃ = m/z 253.14 \rightarrow 47.04, 216.88; M5 = m/z 236.10 \rightarrow 43.97, 61.96.

The accuracy and coefficient of variation (precision) of the assay were determined using quality control samples dissolved in canine plasma or urine prepared in replicates of three at multiple concentrations. The accuracy for plasma (untreated and deconjugated) samples was 106, 98, 102 and 106% for tramadol, M1, M2 and M5 respectively at 5, 50 and 500 ng/mL concentration. The precision of the assay was 5.6, 3.2, 13 and 5.8% for tramadol, M1, M2 and M5 respectively at 5, 50 and 500 ng/mL concentration. The assay was linear over the quantified range of 1 to 1,000 ng/mL. The accuracy of the assay for urine (untreated and deconjugated) was 102, 95, 102 and 103% for tramadol, M1, M2 and M5 respectively at 4, 40, 400 and 4,000 ng/mL concentrations. The precision of the assay was 1.2, 2.3, 3.3 and 7.6% for tramadol, M1, M2 and M5 respectively at 4, 40, 400 and 4,000 ng/mL concentrations. The assay was linear over the quantified range of 0.8 to 8,000 ng/mL. The accuracy of the plasma fluconazole assay was 98% and the precision was 5% at 400, 2,000 and 8,000 ng/mL. The assay was linear over the quantified range of 400 to 10,000 ng/mL.

Tramadol and metabolite conjugate concentrations (expressed as mass equivalents of the parent compound) were calculated by subtracting the untreated concentration from the β -glucuronidase treated concentration for each plasma and urine sample.

Statistical analyses

Statistical analyses were performed using Sigmaplot 13 software (Systat, San Jose, CA). Graphs were prepared using Graph Pad Prism 7 (La Jolla, CA). Data were summarized as the median and 25%-75% interquartile range. The geometric mean ratio (GMR) and the 90%

DMD # 83444

confidence interval of the GMR were also calculated for plasma and urine drug metabolite concentrations obtained after fluconazole pre-treatment divided by concentrations obtained after the placebo pre-treatment (in the same animal). Plasma and urine concentrations that were less than the lower limit of quantitation (LLOQ) were set to zero for descriptive statistics and were set to one-half of the LLOQ value to calculate the GMR. Paired t-tests or Wilcoxon signed rank tests were used to compare pharmacokinetic data between fluconazole and placebo pre-treatments. The Wilcoxon signed rank test was used instead of the paired t-test if the data set failed the Shapiro-Wilk test for normality or the Brown-Forsythe test for equal variance. Data were rank transformed if the data set failed the Shapiro-Wilk test for normality or the Brown-Forsythe test for equal variance. A P-value of less than 0.05 was considered statistically significant.

DMD # 83444

RESULTS

In vitro screen to identify selective inhibitors of tramadol metabolic pathways

An *in vitro* approach with pooled DLMs was used initially to identify a compound that could potentially inhibit M2 formation from tramadol and M5 formation from M1 without affecting M1 formation from tramadol. Eighty-six compounds that could potentially be administered simultaneously with tramadol in the clinical setting, including antibiotics, sedatives, chemotherapeutics, anesthetics, analgesics, anticonvulsants, antidepressants, and antifungals (among others), were initially screened at two concentrations (1 and 100 μM) for their ability to inhibit M1 and M2 formation from tramadol in DLMs when compared with incubations without any inhibitor added (Table 1). Compounds were then categorized according to their inhibition potency (ability to decrease activity by more than 50% at 1 μM or 100 μM inhibitor concentration) and by their selectivity (ability to inhibit by more than 50% M1 formation only, M2 formation only, or both M1 and M2 formation). As shown in Table 2, fluconazole was the only compound out of the 85 tested, that decreased M2 formation from tramadol by more than 50% at the lowest inhibitor concentration tested (1 μM) without affecting M1 formation (less than 50% decrease) at the highest concentration tested (100 μM).

These results for fluconazole were then corroborated by evaluating the rates of formation of M1 and M2 from tramadol in DLMs over a much wider range of fluconazole concentrations (0.001-1000 μM) to estimate IC_{50} values. We also evaluated effects on M5 formation from both M1 and M2 using a similar approach to determine whether fluconazole would also selectively inhibit M1 N-demethylation. As shown in Fig. 1 (panel A) fluconazole potently and selectively inhibited the formation of M2 from tramadol ($\text{IC}_{50} = 0.40 \pm 0.04 \mu\text{M}$) and M5 formation from M1

DMD # 83444

($IC_{50} = 0.24 \pm 0.02 \mu\text{M}$) when compared with the much lower potency of inhibiting M1 formation from tramadol ($IC_{50} = 102 \pm 34 \mu\text{M}$) and M5 formation from M2 ($IC_{50} = 75 \mu\text{M}$).

Finally, the mechanism of inhibition of fluconazole and the inhibition constant (K_i) were determined for M2 formation from tramadol by evaluating multiple inhibitor and substrate concentrations and determining the inhibition model that best fit the data. As shown in Fig. 1 (panel B), a competitive inhibition model best described the data ($K_m = 73 \pm 8.8 \mu\text{M}$; $V_{max} = 479 \pm 18 \text{ pmoles / min / mg protein}$, $K_i = 0.11 \pm 0.02 \mu\text{M}$; adjusted $R^2 = 0.9809$; $P < 0.0001$). Unfortunately, it was not possible to determine the K_i and mechanism of inhibition by fluconazole of M5 formation from M1 because of the slow reaction velocity, which greatly limited assay precision and accuracy.

Fluconazole-tramadol interaction in vivo study

All 12 enrolled dogs completed the study. Only minor adverse events, including mild sedation, gastrointestinal upset, and some skin irritation at the site of the thermal heat probe, were observed during the study or were reported by the owners after study completion. All dogs were reported by the owners to show normal behavior by the following day after each treatment. Blood samples were successfully collected from all dogs without any complications. However, a urine sample could not be obtained within the allotted study time from dog 11 after the placebo/tramadol treatment. Average (range) plasma fluconazole concentrations were 4.5 (3.2 – 6.8) $\mu\text{g / mL}$ before tramadol administration, 4.9 (3.4 – 7.0) $\mu\text{g / mL}$ at 1 hour after tramadol administration, and 6.0 (3.9 – 9.8) $\mu\text{g / mL}$ at 4 hours after tramadol administration, indicating good compliance by the owners with fluconazole pretreatment dosing. Urine and plasma samples from one dog (Dog 7) obtained after fluconazole pretreatment did not show quantifiable tramadol or metabolite concentrations. However, the same plasma samples contained fluconazole concentrations that

DMD # 83444

were similar to concentrations reported for other dogs. Consequently, it was concluded that this dog had not received the intended dose of tramadol after the fluconazole dose and so the results for this dog were not included in the final analysis.

Effect of fluconazole on plasma and urine concentrations of tramadol and metabolites.

Median (25% - 75%) concentrations and fluconazole/placebo GMR (90% confidence interval) values for tramadol and metabolites measured in plasma samples at one hour and 4 hours after tramadol administration are given in Tables 3 and 4 (respectively). Similar summary values for urine samples collected at 4 hours are shown in Table 5. At one hour after tramadol administration (Table 3) the median plasma concentration of M1 (but not any other compound measured) showed a small but statistically significant ($P = 0.047$) increase after fluconazole pretreatment compared with placebo pre-treatment. However, at 4 hours after tramadol administration (Table 4), there were marked and statistically significant increases in median plasma tramadol (31-fold higher), M1 (39-fold higher), and M1 conjugate (11-fold higher) concentrations. Conversely, there were marked and statistically significant decreases in median plasma M2 (11-fold lower), M2 conjugate (4-fold lower), M5 (3-fold lower), and M5 conjugate (7-fold lower) concentrations. There were no changes in tramadol conjugate concentrations.

The changes observed for individual dogs at 4 hours in plasma unconjugated tramadol, M1, M2, and M5 concentrations with fluconazole versus placebo pretreatment are shown in Fig. 2. The direction of change (i.e. increase) in plasma tramadol and M1 concentrations were identical for all dogs (Fig. 2A and 2B). Most dogs also showed a decrease in M2 and M5 concentrations (Fig. 2C and 2D). However, Dog 12 showed an increase in plasma M2 and M5 concentrations, while Dog 9 showed an increase in M5 concentrations, with fluconazole versus placebo pretreatment. Compared with other dogs, Dog 12 also showed the lowest plasma M2

DMD # 83444

concentration, while both Dog 9 and Dog 12 showed the lowest plasma M5 concentrations after placebo pretreatment.

Changes in urine tramadol and metabolite concentrations with fluconazole pretreatment (Table 5) were generally similar to the changes observed (above) for the 4-hour plasma concentrations. There were marked and statistically significant increases in median urinary tramadol (35-fold higher), M1 (33-fold higher), and M1 conjugate (5-fold higher) concentrations. Conversely, there were marked and statistically significant decreases in median urinary M2 (28-fold lower) and M5 (12-fold lower) concentrations. There were no changes in median tramadol, M2 conjugate or M5 conjugate concentrations.

The changes observed for individual dogs in urinary tramadol, M1, M2, and M5 concentrations with fluconazole pretreatment are shown in Fig. 3. Similar to the 4-hour plasma results, the direction of change (i.e. increase) in plasma tramadol and M1 concentrations were identical for all dogs (Fig. 3A and 3B). Most dogs also showed a decrease in M2 and M5 concentrations (Fig. 3C and 3D) except for Dog 1 where small increases (less than 2-fold) in urinary M2 and M5 concentrations were observed. Dog 1 also showed the highest urinary M2 and M5 concentrations after fluconazole pretreatment when compare to results for all other dogs.

The relative proportions of tramadol, M1, M2, and M5 (summed unconjugated plus conjugated for each) expressed as a molar percentage of the total amount of measured tramadol and metabolites in the 4-hour urine samples from individual dogs are shown in Figure 4. After placebo pretreatment (Fig. 4A), M5 showed the highest median molar proportion (67%) followed by M2 (26%), with tramadol (4%) and M1 (4%) showing the lowest median molar percentages. However, after fluconazole pretreatment (Fig. 4B), both tramadol (44%) and M1 (37%) showed

DMD # 83444

the highest median molar proportion in urine samples, while M5 (12%) and M2 (1%) median molar percentages were much lower.

Finally, the relative concentrations of conjugated to unconjugated tramadol, M1, M2, and M5 in urine expressed as a molar ratio are given in Table 6. After placebo pretreatment, M1 showed a high median molar ratio (8.3), M5 had a much lower median ratio (1.2), while median ratios were very low (<0.1) for both tramadol and M2. After fluconazole pretreatment, there was a significant reduction in the M1 median molar ratio by 66% ($P=0.002$), while the M5 median ratio was unchanged ($P=0.002$). A decrease and an increase in the median ratios for tramadol and M2 ratios (respectively) were also observed, although the changes were close to the statistical significance threshold ($P = 0.027$ and 0.049) reflecting high inter-individual variability in the change.

DMD # 83444

DISCUSSION

Few published studies have explored the potential for a beneficial pharmacokinetic interaction to enhance the therapeutic properties of a drug in veterinary patients (some examples include (Kukanich et al., 2011; Radwanski et al., 2011)). In most instances, known CYP inhibitors (usually based on human *in vitro* and *in vivo* studies) are administered orally to decrease first pass metabolism and increase systemic availability, thereby decreasing the required dose of a second (often costlier) drug that has poor systemic availability by the oral route. Relatively non-specific potent CYP inhibitors can often achieve this goal. However, in this study the primary goal was to increase plasma concentrations of an active metabolite (M1) that is formed by CYPs. Therefore, we needed a more CYP-selective approach to inhibit alternative pathways of tramadol and M1 metabolism, without inhibiting M1 formation from tramadol.

Rather than simply choosing CYP-selective inhibitors for *in vivo* testing based solely on available human data, we first used a species-specific *in vitro* approach with canine liver microsomes to identify pathway selective inhibitor candidates. This was followed by a proof-of-principle study in healthy dogs to test the effect of the best candidate on tramadol metabolism *in vivo*. After screening a large number of compounds, we were able to identify only one compound (fluconazole) that potently ($IC_{50} < 1\mu M$) inhibited the formation of M2 from tramadol and M5 from M1 while minimally affecting the formation of M1 from tramadol ($IC_{50} > 100\mu M$). There were also several other compounds (artemisinin, carprofen, dexmedetomidine, and propofol) that showed the desired selectivity but only at the higher inhibitor concentration tested (100 μM). Although we prioritized fluconazole for further *in vitro* (IC_{50} and K_i) and *in vivo* testing study because of higher inhibition potency, these other compounds could be considered for future evaluation.

DMD # 83444

The *in vivo* study pharmacokinetic results completely confirmed the predictions we derived from the *in vitro* model (summarized in Figure 5). Markedly higher plasma and urine tramadol concentrations are consistent with overall increased systemic availability of orally administered tramadol via inhibition of metabolism to M2. In prior work (Perez Jimenez et al., 2016), we showed that M2 formation is mediated primarily by CYP2B11 and CYP3A12, which are both highly expressed in tissues that contribute to first-pass extraction of drug after oral administration, including intestinal mucosa and liver (Heikkinen et al., 2015). A previous study showed that the systemic availability of tramadol in dogs after oral administration (at the same dose used here) is very low, averaging only 2.6% (KuKanich et al., 2017). Oral co-administration of tramadol in that study with CYP inhibitors, including ketoconazole and cimetidine, resulted in about a 5-fold increase in tramadol systemic availability to average 18% and 20% (respectively). Although we did not measure full plasma concentration-time profiles (i.e. area under the curve; AUC) to allow for an accurate calculation of relative systemic availability, plasma tramadol concentrations in this study measured at 1 hour and 4 hours increased on average by 5.6-fold and 31-fold (respectively) with fluconazole. Consequently, enhancement of systemic availability by fluconazole was at least similar to or perhaps as much as 5-fold greater than for ketoconazole or cimetidine (i.e. to as high as about 80%).

In addition to higher tramadol concentrations, we also observed marked (up to 40-fold) increases in plasma and urine M1 concentrations with fluconazole. This effect is likely a consequence of increased CYP2D15 substrate (i.e. tramadol) availability because of shunting of tramadol metabolism away from the M2 pathway, as well as inhibition of further metabolism of M1 to M5. M1 can also be metabolized by conjugation pathways, including glucuronidation and sulfation (Grond and Sablotzki, 2004). In agreement with prior studies (Grond and Sablotzki,

DMD # 83444

2004; Giorgi et al., 2009), our results showed that M1 is primarily found as conjugates in the urine (Tables 5 and 6), and has extended those findings to include plasma conjugates (Tables 3 and 4). Consequently, conjugation is likely an important mechanism for elimination of M1 in dogs, and inhibition of M1 conjugation by fluconazole would be another mechanism to explain increased M1 plasma and urine concentrations. Although we did not directly test whether fluconazole inhibited M1 conjugation, we did observe a 66% decrease in the M1 conjugated/unconjugated concentration ratio with fluconazole treatment compared with placebo, which is consistent with enzymatic inhibition. However, these lower ratios could also be explained by saturation of conjugation pathways resulting from increased substrate (i.e. M1) formation. Interestingly, M1 was shown previously to be glucuronidated primarily by UGT2B7 in human liver (Lehtonen et al., 2010), and fluconazole is a selective inhibitor of UGT2B7 (Uchaipichat et al., 2006). M1 is also conjugated by sulfation, although this appears to occur primarily in the intestinal mucosa, rather than in the liver or kidney, and so may not contribute greatly to systemic clearance, at least in humans (Rasool et al., 2017). It is unclear whether fluconazole can inhibit sulfotransferases.

Several other research studies have attempted to modify tramadol and metabolite pharmacokinetics in dogs by co-administering selected food extracts or drugs (Giorgi et al., 2011; KuKanich et al., 2017). In the first study (Giorgi et al., 2011), tramadol was co-administered with dried grapefruit juice. Their premise was that certain grapefruit constituents known to inhibit human CYP3A would also inhibit canine CYP3A thereby promoting metabolism of tramadol to M1 by CYP2D. However, they appreciated only a negligible effect of grapefruit on tramadol and M1 concentrations and no effect on M2 or M5 concentrations (Giorgi et al., 2011). Although they had no direct evidence at the time, their underlying assumptions were partially correct in that canine CYP2D15 metabolizes tramadol to M1, and canine CYP3A12 contributes to the

DMD # 83444

metabolism of tramadol to M2 (Perez Jimenez et al., 2016). However, additional canine CYPs, particularly CYP2B11, metabolize tramadol to M2, which may have limited the impact of any CYP3A inhibition by grapefruit. Interestingly, administration of bergamottin, the principal CYP inhibitor in grapefruit juice, to Beagle dogs for 10 days resulted in a modest decrease in hepatic microsomal CYP3A activity consistent with enzyme inhibition (Sahi et al., 2002). However, there was also a substantial increase in hepatic CYP2B activities, presumably caused by enzyme induction.

In the second study, tramadol was orally co-administered with ketoconazole or cimetidine (both assumed to be CYP3A inhibitors) to evaluate effects on tramadol and metabolite pharmacokinetics (KuKanich et al., 2017). They observed increases in tramadol plasma concentrations with both inhibitors, but still well below the minimum tramadol concentration of 228 ng/ml associated with analgesia in humans (Grond et al., 1999). There were also some increases in mean maximal plasma concentrations (C_{max}) for M1 from 1.8 ng / mL to 2.5 ng / mL (with ketoconazole) and to 6.6 ng / mL (with cimetidine). However, those M1 concentrations were below what was considered the minimal effective concentration in humans of 10 ng/ml (Scott and Perry, 2000). Ketoconazole also resulted in significant increases in plasma M2 concentrations (C_{max} and AUC) and decreases in M5 concentrations (C_{max} but not AUC), which contrasts with the decreases in both M2 and M5 plasma concentrations observed in this study. We have previously shown that M2 is converted to M5 exclusively by CYP2D15 (Perez Jimenez et al., 2018). In contrast to fluconazole, which had a minimal effect on M2 metabolism to M5 at concentrations up to 10 μ M in this study (Figure 1A), ketoconazole was reported to inhibit CYP2D15 with a potency ($IC_{50} = 0.47 \mu$ M) that was similar to or greater than potencies for all other CYPs evaluated including CYP1A, CYP2C, CYP2B, and CYP3A (Aidasani et al., 2008).

DMD # 83444

Consequently, increased plasma M2 concentrations observed with co-administration of ketoconazole with tramadol could be explained by inhibition of CYP2D15 mediated metabolism of M2 to M5

The median plasma M1 concentration at 4 hours after tramadol with fluconazole pretreatment was 54 ng / mL in the current study, which is higher than that achieved in all the previous studies evaluating effects of tramadol on nociceptive thresholds (Kukanich and Papich, 2011; Kogel et al., 2014; Schutter et al., 2017). This is also within the plasma M1 concentration range of 36 to 84 ng / mL associated with clinical pain relief in humans (Grond et al., 1999) (Lehmann et al., 1990). However, it is somewhat less than the median effective plasma M1 concentration of 113 ng / mL that was reported for cats using a thermal threshold testing method (Pypendop et al., 2009).

There are several limitations to this study. Firstly, we measured tramadol concentrations at only 2 time points and so it cannot be determined whether tramadol half-life is more prolonged with fluconazole co-administration. This would dictate whether dose and/or dose interval adjustments are needed with repeated dosing, which is more commonly used for treatment of pain. Secondly, we only evaluated a single tramadol dose, and there is some prior evidence for increased tramadol clearance in dogs with repeated dosing (Matthiesen et al., 1998). Thirdly, it is not yet clear whether increased tramadol and M1 concentrations will lead to increased analgesic efficacy. Consequently, future studies are needed to determine whether adding fluconazole can enhance the analgesic efficacy of tramadol in healthy dogs (such as through nociceptive threshold testing) and in clinical patients experiencing pain.

DMD # 83444

AUTHOR CONTRIBUTIONS

Participated in research design: Perez, Mealey, Grubb, Greene, Court.

Conducted experiments: Perez, Kukanich, Joo

Contributed new reagents or analytic tools: None.

Performed data analysis: Perez, Court.

Wrote or contributed to the writing of the manuscript: Perez, Mealey, Grubb, Greene, Court,
Kukanich, Joo

DMD # 83444

REFERENCES

- Aidasani D, Zaya MJ, Malpas PB, and Locuson CW (2008) In vitro drug-drug interaction screens for canine veterinary medicines: evaluation of cytochrome P450 reversible inhibition. *Drug Metab Dispos* **36**:1512-1518.
- Aronson MD (1997) Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. *Clin Ther* **19**:420-432; discussion 367-428.
- Cagnardi P, Villa R, Zonca A, Gallo M, Beccaglia M, Luvoni GC, Vettorato E, Carli S, Fonda D, and Ravasio G (2011) Pharmacokinetics, intraoperative effect and postoperative analgesia of tramadol in cats. *Res Vet Sci* **90**:503-509.
- Court MH, Von Moltke LL, Shader RI, and Greenblatt DJ (1997) Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. *Biopharm Drug Dispos* **18**:213-226.
- Davila D, Keeshen TP, Evans RB, and Conzemius MG (2013) Comparison of the analgesic efficacy of perioperative firocoxib and tramadol administration in dogs undergoing tibial plateau leveling osteotomy. *J Am Vet Med Assoc* **243**:225-231.
- Delgado C, Bentley E, Hetzel S, and Smith LJ (2014) Comparison of carprofen and tramadol for postoperative analgesia in dogs undergoing enucleation. *J Am Vet Med Assoc* **245**:1375-1381.
- Evangelista MC, Silva RA, Cardozo LB, Kahvegian MA, Rossetto TC, Matera JM, and Fantoni DT (2014) Comparison of preoperative tramadol and pethidine on postoperative pain in cats undergoing ovariohysterectomy. *BMC Vet Res* **10**:252.

DMD # 83444

- Gaynor JS (2008) Control of cancer pain in veterinary patients. *Vet Clin North Am Small Anim Pract* **38**:1429-1448, viii.
- Giorgi M, Del Carlo S, Saccomanni G, Lebkowska-Wieruszewska B, and Kowalski CJ (2009) Pharmacokinetic and urine profile of tramadol and its major metabolites following oral immediate release capsules administration in dogs. *Vet Res Commun* **33**:875-885.
- Giorgi M, MacCheroni M, Del Carlo S, Yun HI, and Saccomanni G (2011) Effect of oral co-administration of frozen-dried grapefruit juice on pharmacokinetics of tramadol in dogs. *IJVR* **12**:8-15.
- Grond S, Meuser T, Uragg H, Stahlberg H, and Lehmann K (1999) serum concentrations of tramadol enantiomers during patient controlled analgesia. *Br J Clin Pharmacol* **48**:254-258.
- Grond S and Sablotzki A (2004) Clinical pharmacology of tramadol. *Clin Pharmacokinet* **43**:879-923.
- Heikkinen AT, Friedlein A, Matondo M, Hatley OJ, Petsalo A, Juvonen R, Galetin A, Rostami-Hodjegan A, Aebersold R, Lamerz J, Dunkley T, Cutler P, and Parrott N (2015) Quantitative ADME proteomics - CYP and UGT enzymes in the Beagle dog liver and intestine. *Pharm Res* **32**:74-90.
- Kogel B, Terlinden R, and Schneider J (2014) Characterisation of tramadol, morphine and tapentadol in an acute pain model in Beagle dogs. *Vet Anaesth Analg* **41**:297-304.
- KuKanich B, KuKanich K, and Black J (2017) The effects of ketoconazole and cimetidine on the pharmacokinetics of oral tramadol in greyhound dogs. *J Vet Pharmacol Ther* **40**:e54-e61.

DMD # 83444

Kukanich B, Kukanich KS, and Rodriguez JR (2011) The effects of concurrent administration of cytochrome P-450 inhibitors on the pharmacokinetics of oral methadone in healthy dogs.

Vet Anaesth Analg **38**:224-230.

Kukanich B and Papich MG (2011) Pharmacokinetics and antinociceptive effects of oral tramadol hydrochloride administration in Greyhounds. *Am J Vet Res* **72**:256-262.

Lamont LA (2008) Multimodal pain management in veterinary medicine: the physiologic basis of pharmacologic therapies. *Vet Clin North Am Small Anim Pract* **38**:1173-1186, v.

Lehmann K, Kratzenberg U, Schroeder-Back B, and Horrichs-Haermeyer G (1990) postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations *Clin J Pain* **6**:212-220.

Lehtonen P, Sten T, Aitio O, Kurkela M, Vuorensola K, Finel M, and Kostainen R (2010) Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol. *Eur J Pharm Sci* **41**:523-530.

Matthiesen T, Wohrmann T, Coogan TP, and Uragg H (1998) The experimental toxicology of tramadol: an overview. *Toxicol Lett* **95**:63-71.

Perez Jimenez TE, Mealey KL, Schnider D, Grubb TL, Greene SA, and Court MH (2018) Identification of canine cytochrome P-450s (CYPs) metabolizing the tramadol (+)-M1 and (+)-M2 metabolites to the tramadol (+)-M5 metabolite in dog liver microsomes. *J Vet Pharmacol Ther* 1-10

Perez Jimenez TE, Mealey KL, Grubb TL, Greene SA, and Court MH (2016) Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs). *Drug Metab Dispos* **44**:1963-1970.

DMD # 83444

Pypendop BH, Siao KT, and Ilkiw JE (2009) Effects of tramadol hydrochloride on the thermal threshold in cats. *Am J Vet Res* **70**:1465-1470.

Radwanski NE, Cerundolo R, Shofer FS, Hanley MJ, and Court MH (2011) Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. *Am J Vet Res* **72**:687-693.

Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, and Vaught JL (1992) Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. *J Pharmacol Exp Ther* **260**:275-285.

Rasool MI, Bairam AF, Kurogi K, and Liu MC (2017) On the sulfation of O-desmethyltramadol by human cytosolic sulfotransferases. *Pharmacol Rep* **69**:953-958.

Sahi J, Reyner EL, Bauman JN, Gueneva-Boucheva K, Burleigh JE, and Thomas VH (2002) The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. *Drug Metab Dispos* **30**:135-140.

Schutter AF, Tunsmeier J, and Kastner SBR (2017) Influence of tramadol on acute thermal and mechanical cutaneous nociception in dogs. *Vet Anaesth Analg* **44**:309-316.

Scott LJ and Perry CM (2000) Tramadol - A review of its use in perioperative pain. *Drugs* **60**:139-176.

Subrahmanyam V, Renwick AB, Walters DG, Young PJ, Price RJ, Tonelli AP, and Lake BG (2001) Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. *Drug Metab Dispos* **29**:1146-1155.

Uchaipichat V, Winner LK, Mackenzie PI, Elliot DJ, Williams JA, and Miners JO (2006) Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs

DMD # 83444

from in vitro data: the effect of fluconazole on zidovudine glucuronidation. *Br J Clin Pharmacol* **61**:427-439.

Venkatakrishnan K, Von Moltke LL, and Greenblatt DJ (2001) Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. *J Clin Pharmacol* **41**:1149-1179.

DMD # 83444

FOOTNOTES

Dr. Perez was supported in these studies by a Morris Animal Foundation Fellowship Training Grant [D16CA-401], and a WSU College of Veterinary Medicine Department of Veterinary Clinical Sciences graduate student grant. Dr. Court was supported by the US National Institutes of Health grant [GM102130] and the William R. Jones endowment to Washington State University College of Veterinary Medicine.

DMD # 83444

FIGURE LEGENDS

Figure 1. (A). Selective inhibition of the major primary (tramadol to M1 and to M2) and secondary (M1 to M5 and M2 to M5) cytochrome P450 dependent metabolic pathways by fluconazole in pooled dog liver microsomes (N=59). Shown are the rates of metabolite formation (mean \pm SD of triplicate independent determinations) in the presence of inhibitor (0.001 to 1000 μ M concentration) expressed as a percentage of the formation rate without inhibitor (control activity). (B). Data used to estimate the inhibition constant (K_i) for inhibition of M2 formation from tramadol by fluconazole in pooled (N=59) dog liver microsomes. Shown are the rates of metabolite formation (mean \pm SD of triplicate determinations) in the absence and presence of inhibitor (0.1, 1, 10, and 100 μ M fluconazole), each at different substrate concentrations (5, 10, 20, 50, 100, 200, 500 μ M tramadol). The data best fit a competitive inhibition model by non-linear regression analysis with a K_i of $0.11 \pm 0.02 \mu$ M.

Figure 2. Plasma concentrations (ng / mL) of tramadol (A), M1 (B), M2 (C), and M5 (D) measured at 4 hours after administration of tramadol (5 mg / kg bodyweight) orally to 11 dogs twice, after pre-treatment with fluconazole and after placebo separated by a 2-week washout period. Open circles are plasma concentration values for each dog measured after placebo and fluconazole pre-treatments, and connected by a line to show the change that occurred within individual subjects. Also shown are *P*-values obtained using the Wilcoxon signed ranked test comparing fluconazole to placebo pre-treatments.

Figure 3. Urine concentrations (ng / mL) of tramadol (A), M1 (B), M2 (C), and M5 (D) measured at 4 hours after administration of tramadol (5 mg / kg bodyweight) orally to 10 dogs twice, after pre-treatment with fluconazole and after placebo separated by a 2-week washout period. Note that a urine sample could not be obtained from dog 11 after placebo pre-treatment. Open circles are

DMD # 83444

urine concentration values for each dog measured after placebo and fluconazole pre-treatments, and connected by a line to show the change that occurred within individual subjects. Also shown are *P*-values obtained using the Wilcoxon signed ranked test comparing fluconazole to placebo pre-treatments.

Figure 4. Relative proportions of tramadol, M1, M2, and M5 (unconjugated plus conjugated) measured in urine samples at 4 hours after administration of tramadol (5 mg / kg bodyweight) orally to 10 dogs twice, after pre-treatment with placebo and after fluconazole separated by a 2-week washout period. Each stacked bar show values for individual dogs expressed as a molar percent of total measured compounds for that urine sample.

Figure 5. Effect of fluconazole on tramadol metabolism in dogs based on the results of this study. The primary pathway for tramadol metabolism is N-demethylation to M2 followed by O-demethylation to M5. M2 and M5 (and their phase 2 metabolism conjugates) are the most abundant metabolites found in dog plasma and urine. O-demethylation of tramadol to M1 followed by N-demethylation to M5 is a minor pathway, and only low concentrations of M1 and its conjugates are detected in plasma and urine. Fluconazole was identified as a potent inhibitor of M2 formation from tramadol and M5 formation from M1 in dog liver microsomes without inhibiting the other two pathways. Oral pre-treatment of dogs with fluconazole markedly increased plasma and urine concentrations of tramadol and M1, and decreased M2 and M5 concentrations.

DMD # 83444

Table 1. Results of an in vitro screening assay to identify compounds that selectively inhibit M2 formation (but not M1 formation) from tramadol by dog liver microsomes. Shown are the formation rates of M1 and M2 from tramadol in pooled dog liver microsomes incubated with each of 85 different compounds at 1 μ M and 100 μ M inhibitor concentration. Results are presented as the percentage of control (no inhibitor added) activity and are the average of triplicate determinations conducted in a single experiment.

Inhibitor	M1 formation (% control)		M2 formation (% control)	
	1 μ M inhibitor	100 μ M inhibitor	1 μ M inhibitor	100 μ M inhibitor
Acepromazine	92	20	94	84
Acetaminophen	95	92	93	95
Alfaxalone	93	51	90	68
Amytriptylline	95	0.9	148	25
Artemisinin	95	66	73	7
Acetylsalicylic acid	93	94	91	96
Atipamezole	18	0.1	6	5
Bupivacaine	32	1	91	23
Buprenorphine	84	4	97	43
Bupropion	94	16	93	47
Carbamazepine	95	54	91	52
Carprofen	96	61	95	46
Chloramphenicol	100	44	95	13
Cimetidine	99	37	97	65

DMD # 83444

Ciprofloxacin	95	77	91	92
Citalopram	6	0.3	92	13
Clarithromycin	99	95	104	98
Clopidrogel	95	28	62	8
Codeine	100	89	99	78
Curcumin	96	48	94	59
Cyclophosphamide	90	89	85	76
Deracoxib	78	9	77	20
Desipramine	37	1	49	6
Dexamethasone	91	67	92	81
Dexmedetomidine	99	86	90	8
Dextrometorphan	65	1	90	30
Diazepam	93	32	81	10
Diclofenac	101	136	101	71
Diethyldithiocarbamate	93	80	95	65
Dopamine	95	46	97	89
Doxepin	82	3	90	36
Doxycycline	97	73	98	88
Diphenhydramine	87	5	90	37
Efavirenz	122	48	52	10
Erythromycin	94	89	100	92
Fenoprofen	93	61	90	71
Fentanyl	82	12	88	67

DMD # 83444

Firocoxib	90	44	97	78
Fluconazole	97	14	10	3
Flurbiprofen	94	145	102	99
Fluoxetine	62	2	81	12
Furosemide	90	86	96	85
Gabapentin	102	88	101	88
Hydromorphone	89	55	88	78
Ibuprofen	95	81	89	89
Imipramine	48	1	93	81
Itraconazole	87	71	84	63
Ketamine	94	45	62	14
Ketoconazole	47	2	84	19
Ketoprofen	94	83	92	60
Ketorolac	94	89	90	84
Ketotifen	63	2	85	25
Lamotrigine	92	54	110	81
Levomedetomidine	36	0.2	10	9
Lidocaine	91	50	91	73
Lorazepam	89	16	108	70
Maropitant	7	1	82	63
Meloxicam	93	83	90	80
Methadone	67	2	87	21
Metoclopramide	106	43	105	106

DMD # 83444

Metronidazole	105	99	106	79
Midazolam	91	5	69	24
Morphine	95	85	96	91
Mycophenolic acid	90	60	117	79
Naproxen	90	65	114	99
Norfloxacin	96	82	98	87
Ofloxacin	94	82	94	88
Omeprazole	105	28	112	57
Oxazepam	92	39	139	78
Paroxetine	27	1	20	11
Phenacetin	85	49	124	79
Piperine	84	70	126	76
Propofol	93	72	91	22
Quinidine	26	2	102	77
Quinine	27	0.2	57	12
Selegiline	87	50	92	20
Suprofen	95	99	85	87
Terbinafine	91	40	99	63
Thio-TEPA	99	100	98	90
Trazadone	103	31	110	54
Trifluoperazine	34	1	88	25
Valproic Acid	97	99	98	88
Vinblastine	95	21	99	87

DMD # 83444

Xylazine	93	17	97	41
Zomepirac	96	93	95	77

DMD # 83444

Table 2. Inhibitors of M1 and/or M2 formation from tramadol by pooled dog liver microsomes categorized by inhibition potency. Inhibitors are listed according to whether they decrease the indicated activities by at least 50% (compared to no inhibitor added) at 1 μ M inhibitor concentration and/or also at 100 μ M inhibitor concentration. Inhibitors are also grouped by whether they inhibit M1 formation only, M2 formation only, or both M1 and M2 formation by at least 50% at that inhibitor concentration. Inhibition data used to generate this table are shown in Table 1.

Inhibitor concentration	Compounds that inhibit M1 formation (only) by more than 50%	Compounds that inhibit both M1 and M2 formation by more than 50%	Compounds that inhibit M2 formation (only) by more than 50%
1 μ M	Bupivacaine	Atipamezole	Fluconazole
	Citalopram	Desipramine	
	Imipramine	Levomedetomidine	
	Ketoconazole	Paroxetine	
	Maropitant		
	Quinidine		
	Trifluoperazine		
100 μ M	Acepromazine	Amytriptylline	Artemisinin
	Chloramphenicol	Atipamezole	Carprofen
	Cimetidine	Bupivacaine	Dexmedetomidine
	Curcumin	Buprenorphine	Fluconazole
	Dopamine	Bupropion	Propofol
	Fentanyl	Citalopram	Selegiline

DMD # 83444

Firocoxib	Clopidrogel
Fluoxetine	Chloramphenicol
Lorazepam	Deracoxib
Maropitant	Desipramine
Metoclopramide	Dextromethorphan
Omeprazole	Diazepam
Oxazepam	Doxepin
Phenacetin	Diphenhydramine
Quinidine	Efavirenz
Terbinafine	Fluconazole
Trazadone	Fluoxetine
Vinblastine	Imipramine
	Ketamine
	Ketoconazole
	Ketotifen
	Levomedetomidine
	Methadone
	Midazolam
	Paroxetine
	Quinine
	Trifluoperazine
	Xylazine

DMD # 83444

Table 3. Plasma concentrations (ng / mL) of tramadol (T), M1, M2 and M5 and their respective conjugates (conj.) measured at 1 hour after administration of tramadol (5 mg / kg bodyweight) orally to 11 dogs twice after pretreatment with fluconazole and with placebo separated by a 2-week washout period. Conjugate concentrations are given as mass equivalents of the respective parent (unconjugated) compound. The data are presented as the median and the 25% - 75% interquartile range of concentrations and as the geometric mean ratio (GMR) and 90% confidence interval. The *P*-value indicates the significance of paired comparisons between fluconazole and placebo treatments using the Wilcoxon signed rank test. *A *P*-value of less than 0.05 is considered statistically significant.

Analyte	Plasma concentration (ng/mL)					Plasma concentration ratio	
	Placebo		Fluconazole		<i>P</i> -value	(Fluconazole/Placebo)	
	Median	25% - 75%	Median	25% - 75%		GMR	90% CI
T	0.0	(0.0 - 3.8)	3.0	(0.0 - 305)	0.11	6.6	(1.1 - 40)
T conj.	0.0	(0.0 - 0.0)	0.0	(0.0 - 13)	0.094	3.7	(1.1 - 12)
M1	0.0	(0.0 - 0.0)	2.3	(0.0 - 77)	0.047*	6.1	(1.7 - 21)
M1 conj.	2.5	(0.0 - 7.7)	0.0	(0.0 - 191)	0.91	1.2	(0.25 - 5.5)
M2	0.0	(0.0 - 47)	0.0	(0.0 - 6.7)	0.31	0.51	(0.12 - 2.1)
M2 conj.	1.1	(0.0 - 5.8)	0.0	(0.0 - 1.3)	0.15	0.41	(0.15 - 1.1)
M5	3.9	(0.0 - 81)	0.0	(0.0 - 8.9)	0.078	0.25	(0.069 - 0.92)
M5 conj.	7.5	(1.6 - 169)	0.0	(0.0 - 14)	0.13	0.12	(0.025 - 0.57)

DMD # 83444

Table 4. Plasma concentrations (ng / mL) of tramadol (T), M1, M2 and M5 and their respective conjugates (conj.) measured at 4 hours after administration of tramadol (5 mg / kg bodyweight) orally to 11 dogs twice, after pretreatment with fluconazole and after placebo separated by a 2-week washout period. Conjugate concentrations are given as mass equivalents of the respective parent (unconjugated) compound. The data are presented as the median and the 25% - 75% interquartile range of concentrations and as the geometric mean ratio (GMR) and 90% confidence interval. The *P*-value indicates the significance of paired comparisons between fluconazole and placebo treatments using the Wilcoxon signed rank test. *A *P*-value of less than 0.05 was considered statistically significant.

Analyte	Plasma concentration (ng/mL)					Plasma concentration ratio	
	Placebo		Fluconazole		<i>P</i> -value	(Fluconazole/Placebo)	
	Median	25% - 75%	Median	25% - 75%		GMR	90% CI
T	6.4	(3.0 - 20)	215	(59 - 502)	<0.001*	32	(11 - 98)
T conj.	0.0	(0.0 - 5.5)	13	(0.0 - 57)	0.13	5.8	(0.79 - 42)
M1	0.0	(0.0 - 2.8)	54	(38 - 68)	<0.001*	40	(21 - 76)
M1 conj.	34	(13 - 67)	325	(121 - 764)	<0.001*	12	(5.8 - 24)
M2	83	(33 - 215)	5.4	(1.1 - 18)	0.002*	0.083	(0.033 - 0.21)
M2 conj.	8.8	(0.0 - 40.9)	2.2	(0.0 - 3.8)	0.049*	0.22	(0.061 - 0.82)
M5	79	(40 - 88)	10	(5.7 - 12)	0.005*	0.27	(0.094 - 0.79)
M5 conj.	825	(497 - 1195)	54	(21 - 109)	0.002*	0.12	(0.042 - 0.32)

DMD # 83444

Table 5. Urine concentrations (ng / mL) of tramadol (T), M1, M2 and M5 and their respective conjugates (conj.) measured at 4 hours after administration of tramadol (5 mg / kg bodyweight) orally to 10 dogs twice, after pretreatment with fluconazole and after pretreatment with placebo separated by a 2-week washout period. Conjugate concentrations are given as mass equivalents of the respective parent (unconjugated) compound. The data are presented as the median and the 25% - 75% interquartile range of concentrations and as the geometric mean ratio (GMR) and 90% confidence interval. The *P*-value indicates the significance of paired comparisons between fluconazole and placebo treatments using the Wilcoxon signed rank test. *A *P*-value of less than 0.05 was considered statistically significant.

Analyte	Urine concentration (ng/mL)					Urine concentration ratio	
	Placebo		Fluconazole		<i>P</i> -value	(Fluconazole/Placebo)	
	Median	25% - 75%	Median	25% - 75%		GMR	90% CI
T	144	(11 - 498)	1528	(881 - 8856)	0.002*	36	(10 - 127)
T conj.	0.0	(0.0 - 71)	0.0	(0.0 - 8.2)	0.31	0.87	(0.19 - 3.9)
M1	34	(11 - 102)	728	(328 - 2135)	0.002*	34	(12 - 94)
M1 conj.	473	(126 - 1330)	2048	(895 - 6013)	0.01*	6.4	(2.2 - 18.9)
M2	1284	(522 - 3570)	59	(8.2 - 437)	0.01*	0.034	(0.011 - 0.11)
M2 conj.	218	(0.0 - 717)	15	(6.3 - 39)	0.13	0.40	(0.055 - 2.9)
M5	2968	(1872 - 3802)	224	(81 - 758)	0.006*	0.076	(0.026 - 0.22)
M5 conj.	4227	(859 - 10186)	372	(168 - 3299)	0.32	0.28	(0.056 - 1.4)

DMD # 83444

Table 6. Urine conjugated/unconjugated molar ratios of tramadol, M1, M2 and M5 measured at 4 hours after administration of tramadol (5 mg / kg bodyweight) orally to 10 dogs twice, after pretreatment with fluconazole and after pretreatment with placebo separated by a 2-week washout period. The data are presented as the median and the 25% - 75% interquartile range of concentrations. The *P*-value indicates the significance of paired comparisons between fluconazole and placebo treatments using the Wilcoxon signed rank test. *A *P*-value of less than 0.05 was considered statistically significant.

Analyte	Urine conjugated/unconjugated molar ratio				
	Placebo		Fluconazole		<i>P</i> -value
	Median	25%-75%	Median	25%-75%	
Tramadol	0.014	(0.008 - 0.57)	0.002	(0.0002 - 0.022)	0.027*
M1	8.3	(4.6 - 16)	2.8	(1.1 - 3.9)	0.002*
M2	0.08	(0.01 - 0.34)	0.44	(0.20 - 1.08)	0.049*
M5	1.2	(0.5 - 3.6)	1.7	(0.7 - 3.6)	0.43

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

